Literature DB >> 22350793

Characterization of a new human cell line (CH-3573) derived from a grade II chondrosarcoma with matrix production.

Silvia Calabuig-Fariñas1, Rosario Gil Benso, Karoly Szuhai, Isidro Machado, José Antonio López-Guerrero, Danielle de Jong, Amando Peydró, Teresa San Miguel, Lara Navarro, Antonio Pellín, Antonio Llombart-Bosch.   

Abstract

Chondrosarcomas are malignant cartilage-forming tumors that represent the third most common malignant solid tumor of bone. In patients with grades II and III, local recurrence, increasing tumor size and dedifferentiation have been associated with lower survival rates. These biologically poorly-understood neoplasms vary considerably in clinical presentation and biological behavior. Cytogenetic studies have shown that heterogeneity is related to karyotypic complexity; moreover, alterations in the 9p21 locus and TP53 gene are related to disease progression. Despite the relatively high frequency of chondrosarcoma only a limited number of cell lines exist in the scientific community, limiting the possibility to study hypothesis-derived research or primary drug interaction necessary for pre-clinical studies. We report a chondrosarcoma cell line, CH-3573, derived from a primary tumor that may serve as a useful tool for both in vitro and in vivo models to study the molecular pathogenesis. In addition, xenograft passages in nude mice were studied to characterize the genetic stability over the course of tumor progression. In contrary to other reported cell lines, an important feature of our established cell line was the retained matrix production, a characteristic feature of a conventional grade II chondrosarcoma. The cell line (CH-3573) was characterized by pathological, immunohistochemical and molecular genetic methods.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22350793     DOI: 10.1007/s12253-012-9505-0

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  35 in total

1.  Establishment and characterization of the permanent human cell line C3842 derived from a secondary chondrosarcoma in Ollier's disease.

Authors:  Thomas Kalinski; Sabine Krueger; Antje-Friederike Pelz; Peter Wieacker; Roland Hartig; Martin Röpke; Regine Schneider-Stock; Frank Dombrowski; Albert Roessner
Journal:  Virchows Arch       Date:  2005-02-25       Impact factor: 4.064

2.  Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading.

Authors:  H L Evans; A G Ayala; M M Romsdahl
Journal:  Cancer       Date:  1977-08       Impact factor: 6.860

3.  Cytogenetic aberrations and their prognostic impact in chondrosarcoma.

Authors:  Nils Mandahl; Pelle Gustafson; Fredrik Mertens; Måns Akerman; Bo Baldetorp; David Gisselsson; Sakari Knuutila; Henrik C F Bauer; Olle Larsson
Journal:  Genes Chromosomes Cancer       Date:  2002-02       Impact factor: 5.006

4.  Chondrosarcoma of the urinary bladder and establishment of a human chondrosarcoma cell line (OCUU-6).

Authors:  Shinichi Ikemoto; Kazunobu Sugimura; Naomasa Yoshida; Tatsuya Nakatani
Journal:  Hum Cell       Date:  2004-09       Impact factor: 4.174

5.  Alterations in the regulatory pathway involving p16, pRb and cdk4 in human chondrosarcoma.

Authors:  J Asp; S Inerot; J A Block; A Lindahl
Journal:  J Orthop Res       Date:  2001-01       Impact factor: 3.494

Review 6.  The clinical management of chondrosarcoma.

Authors:  Richard F Riedel; Nicole Larrier; Leslie Dodd; David Kirsch; Salutario Martinez; Brian E Brigman
Journal:  Curr Treat Options Oncol       Date:  2009-02-24

7.  Chondrosarcoma of bone: does the size of the tumor, the presence of a pathologic fracture, or prior intervention have an impact on local control and survival?

Authors:  Ajay Puri; Mandip Shah; Manish G Agarwal; Nirmala A Jambhekar; Prabhudev Basappa
Journal:  J Cancer Res Ther       Date:  2009 Jan-Mar       Impact factor: 1.805

8.  Altered p53 is associated with aggressive behavior of chondrosarcoma: a long term follow-up study.

Authors:  Y Oshiro; V Chaturvedi; D Hayden; T Nazeer; M Johnson; D A Johnston; N G Ordóñez; A G Ayala; B Czerniak
Journal:  Cancer       Date:  1998-12-01       Impact factor: 6.860

9.  Partial deletions of the CDKN2 and MTS2 putative tumor suppressor genes in a myxoid chondrosarcoma.

Authors:  A A Jagasia; J A Block; M O Diaz; T Nobori; S Gitelis; S E Inerot; A P Iyer
Journal:  Cancer Lett       Date:  1996-07-19       Impact factor: 8.679

10.  Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth in vitro.

Authors:  Yvonne M Schrage; Suzanne Lam; Aart G Jochemsen; Anne-Marie Cleton-Jansen; Antonie H M Taminiau; Pancras C W Hogendoorn; Judith V M G Bovée
Journal:  J Cell Mol Med       Date:  2008-06-27       Impact factor: 5.310

View more
  7 in total

1.  An orthotopic mouse model for chondrosarcoma of bone provides an in vivo tool for drug testing.

Authors:  Jolieke G van Oosterwijk; Jacqueline R M Plass; Danielle Meijer; Ivo Que; Marcel Karperien; Judith V M G Bovée
Journal:  Virchows Arch       Date:  2014-10-21       Impact factor: 4.064

2.  Targeting survivin as a potential new treatment for chondrosarcoma of bone.

Authors:  Y de Jong; J G van Oosterwijk; A B Kruisselbrink; I H Briaire-de Bruijn; G Agrogiannis; Z Baranski; A H G Cleven; A-M Cleton-Jansen; B van de Water; E H J Danen; J V M G Bovée
Journal:  Oncogenesis       Date:  2016-05-09       Impact factor: 7.485

3.  No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone.

Authors:  Elisabeth F P Peterse; Arjen H G Cleven; Yvonne De Jong; Inge Briaire-de Bruijn; Jonathan A Fletcher; Erik H J Danen; Anne-Marie Cleton-Jansen; Judith V M G Bovée
Journal:  BMC Cancer       Date:  2016-07-14       Impact factor: 4.430

4.  Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation.

Authors:  Elisabeth F P Peterse; Bertine Niessen; Ruben D Addie; Yvonne de Jong; Arjen H G Cleven; Alwine B Kruisselbrink; Brendy E W M van den Akker; Remco J Molenaar; Anne-Marie Cleton-Jansen; Judith V M G Bovée
Journal:  Br J Cancer       Date:  2018-03-26       Impact factor: 9.075

5.  Establishment and Characterization of a Novel Dedifferentiated Chondrosarcoma Cell Line DDCS2.

Authors:  Xiaoyang Li; Dylan C Dean; Al Ferreira; Scott D Nelson; Francis J Hornicek; Shengji Yu; Zhenfeng Duan
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

6.  Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone.

Authors:  Jolieke G van Oosterwijk; Danielle de Jong; Maayke A J H van Ruler; Pancras C W Hogendoorn; P D Sander Dijkstra; Carla S P van Rijswijk; Isidro Machado; Antonio Llombart-Bosch; Karoly Szuhai; Judith V M G Bovée
Journal:  BMC Cancer       Date:  2012-08-28       Impact factor: 4.430

7.  Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma.

Authors:  Yvonne de Jong; David Monderer; Emeline Brandinelli; Morgane Monchanin; Brendy E van den Akker; Jolieke G van Oosterwijk; Jean Yves Blay; Aurélie Dutour; Judith V M G Bovée
Journal:  Oncogenesis       Date:  2018-09-21       Impact factor: 7.485

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.